{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:04:13Z","timestamp":1760853853644,"version":"3.40.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.neuropharm.2015.10.037","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T11:09:30Z","timestamp":1446548970000},"page":"121-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-8376","authenticated-orcid":false,"given":"Yu-Wen","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Seager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Wojcik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Heman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus F.","family":"Molski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alda","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annapurna","family":"Pendri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Gerritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizbeth","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zaczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Macor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne J.","family":"Bronson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.10.037_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","article-title":"Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies","volume":"20","author":"Abi-Dargham","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/13543776.2012.674514","article-title":"PDE inhibition and cognition enhancement","volume":"22","author":"Blockland","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib4","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.bmcl.2007.02.061","article-title":"PDE-10A inhibitors as insulin secretagogues","volume":"17","author":"Cantin","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib5","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/VHRM.S3160","article-title":"Safety and efficacy of cilostazol in the management of intermittent claudication","volume":"4","author":"Chi","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4137\/CCRPM.S7211","article-title":"Pharmacotherapies for COPD","volume":"7","author":"Ejiofor","year":"2013","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib10","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00213-013-3371-7","article-title":"Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating","volume":"231","author":"Gresack","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib11","doi-asserted-by":"crossref","first-page":"8781","DOI":"10.1021\/jm401234w","article-title":"Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A)","volume":"56","author":"Hu","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuroscience.2006.09.026","article-title":"Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity","volume":"144","author":"Kanes","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s002130100790","article-title":"Drug-induced receptor occupancy: substantial differences in measurements made in\u00a0vivo versus ex\u00a0vivo","volume":"157","author":"Kapur","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.npp.1301099","article-title":"Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP","volume":"32","author":"Kelly","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/mp.2008.124","article-title":"Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia","volume":"14","author":"Kelly","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7015-11-96","article-title":"Phosphodiesterase 4-targeted treatments for autoimmune diseases","volume":"11","author":"Kumar","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2567-y","article-title":"Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test","volume":"221","author":"Langen","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2008.04.014","article-title":"Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance","volume":"55","author":"Lengyel","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.113.211904","article-title":"Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs","volume":"349","author":"Megens","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib21","first-page":"1","article-title":"PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways","volume":"2","author":"Megens","year":"2014","journal-title":"Pharma Res. Per."},{"year":"2000","series-title":"Primate Brain Maps: Structure of the Macaque Brain","author":"Martin","key":"10.1016\/j.neuropharm.2015.10.037_bib22"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib23","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneumeth.2003.12.006","article-title":"Focused microwave irradiation of the brain preserves in\u00a0vivo protein phosphorylation: comparison with other methods of sacrifice and analysis of multiple phosphoproteins","volume":"135","author":"O'Callaghan","year":"2004","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study","volume":"60","author":"Oudiz","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib26","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jacc.2012.07.011","article-title":"Hospital patterns of use of positive inotropic agents in patients with heart failure","volume":"60","author":"Partovian","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"year":"2007","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.neuropharm.2015.10.037_bib27"},{"year":"2001","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.neuropharm.2015.10.037_bib28"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.neuropharm.2013.08.006","article-title":"Selective inhibition of phosphodiesterase 10A impairs appetitive and aversive conditioning and incentive salience attribution","volume":"75","author":"Piccart","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbr.2014.03.016","article-title":"Genetic deletion of PDE10A selectively impairs incentive salience attribution and decreases medium spiny neuron excitability","volume":"268","author":"Piccart","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.nucmedbio.2011.02.005","article-title":"Radiosynthesis and in\u00a0vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A","volume":"38","author":"Plisson","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2967\/jnumed.113.131409","article-title":"Phosphodiesterase 10A PET radioligand development program: from pig to human","volume":"55","author":"Plisson","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","article-title":"Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801","volume":"236","author":"Reneerkens","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib34","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.neuropharm.2011.08.008","article-title":"Selective phosphodiesterase inhibitors improve performance on the ED\/ID cognitive task in rats","volume":"62","author":"Rodefer","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neuropharm.2013.01.011","article-title":"The role of phosphodiesterases in hippocampal synaptic plasticity","volume":"74","author":"Sanderson","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1471-4159.2007.05152.x","article-title":"Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2","volume":"105","author":"Sano","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib37","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension","volume":"43","author":"Sastry","year":"2004","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0929867043456043","article-title":"New antipsychotics and schizophrenia: a review on efficacy and side effects","volume":"11","author":"Serretti","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib42","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/17460441.2.7.1001","article-title":"Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia","volume":"2","author":"Siuciak","year":"2007","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-007-0727-x","article-title":"Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme","volume":"192","author":"Siuciak","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib45","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2009.09.008","article-title":"Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A","volume":"58","author":"Strick","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneumeth.2004.05.007","article-title":"Fast Fos: rapid protocols for single- and double-labeling c-Fos immunohistochemistry in fresh frozen brain sections","volume":"141","author":"Sundquist","year":"2005","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1082-6","article-title":"Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol","volume":"162","author":"Tauscher","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/ecp.13.16","article-title":"Phosphodiesterase inhibitors in clinical urology","volume":"6","author":"\u00dcckert","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2013.10.015","article-title":"Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications","volume":"77","author":"Uthayathas","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib50","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2967\/jnumed.112.118679","article-title":"Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain","volume":"54","author":"Van Laere","year":"2013","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2015.10.037_bib51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00259-012-2270-1","article-title":"Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging","volume":"40","author":"Van Laere","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neuropharm.2015.10.037_bib52","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/138161210790170085","article-title":"Conditioned avoidance response in the development of new antipsychotics","volume":"16","author":"Wadenberg","year":"2010","journal-title":"Curr. Pharm. Des."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081530160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081530160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T02:45:01Z","timestamp":1567305901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081530160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":53,"alternative-id":["S002839081530160X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.037","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}